Peri-implant mucositis Oral Health Peri-implant mucositis
Conditions
Interventions
All participants attend 10 study visits. At the first visit, baseline scores for width of keratinised mucosa (which should be less than 2mm for inclusion of the patient in the study), probing depths a
Sponsors
Geistlich Pharma (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with implant retained mandibular over dentures with at least two fixtures 2. Presence of less than 1mm keratinised mucosa at the implant site 3. Clinical presence of peri-implant mucositis 4. Aged between 50 and 80 years
Exclusion criteria
Exclusion criteria: 1. ASA III and above 2. Smokers 3. Pregnancy 4. Patients on medications recognised to cause Drug Induced Gingival Overgrowth 5. Patients on anti-inflammatory drugs and steroids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Keratinised tissue width is measured using a periodontal probe at baseline and 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Pro-inflammatory cytokine levels around the implants collected on Periopaper strips analysed with V-PLEX Proinflammatory Panel 1 (human) Kit at baseline and 3 months 2. Probing depths measured with a periodontal probe at baseline and 3 months 3. Plaque and bleeding scores measured by observation following probing at baseline, 3, 6 and 12 months. | — |
Countries
United Kingdom
Outcome results
None listed